Lv6
1650 积分 2020-09-22 加入
HER2-ADC and HER2-TKI Overcomes HER2 Amplification as an Acquired Resistance to Zongertinib – A Case Report
1天前
待确认
The evolving immuno-angiogenic paradigm in NSCLC: lessons from ivonescimab
1天前
待确认
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
1天前
待确认
Immunotherapy for advanced-stage squamous cell lung cancer: the state of the art and outstanding questions
1天前
待确认
New promises and challenges in the treatment of advanced non-small-cell lung cancer
1天前
待确认
Evolving roles of MET as a therapeutic target in NSCLC and beyond
1天前
待确认
Advances in systemic therapy for non-small cell lung cancer
1天前
待确认
Current and future therapies for small cell lung carcinoma
1天前
待确认
Immunotherapy for extensive-stage small cell lung cancer: current status, challenges and future strategies
1天前
待确认
The current and emerging immunotherapy paradigm in small-cell lung cancer
1天前
待确认
皖公网安备34019202002308
